dc.creator | Psimadas D., Valotassiou V., Alexiou S., Tsougos I., Georgoulias P. | en |
dc.date.accessioned | 2023-01-31T09:50:51Z | |
dc.date.available | 2023-01-31T09:50:51Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1080/07357907.2018.1430816 | |
dc.identifier.issn | 07357907 | |
dc.identifier.uri | http://hdl.handle.net/11615/78397 | |
dc.description.abstract | Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can “carry” the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa). © 2018 Taylor & Francis Group, LLC. | en |
dc.language.iso | en | en |
dc.source | Cancer Investigation | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044188246&doi=10.1080%2f07357907.2018.1430816&partnerID=40&md5=5f42f6b64d192be7fe497916b1f26f9f | |
dc.subject | antibody | en |
dc.subject | capromab pendetide in 111 | en |
dc.subject | enzyme inhibitor | en |
dc.subject | monoclonal antibody | en |
dc.subject | monoclonal antibody 3 A12 | en |
dc.subject | monoclonal antibody 3 E7 | en |
dc.subject | monoclonal antibody 3 F11 | en |
dc.subject | monoclonal antibody 3C6 | en |
dc.subject | monoclonal antibody J591 | en |
dc.subject | nanobody | en |
dc.subject | peptide | en |
dc.subject | prostate specific membrane antigen | en |
dc.subject | radioisotope | en |
dc.subject | radiopharmaceutical agent | en |
dc.subject | unclassified drug | en |
dc.subject | glutamate carboxypeptidase II | en |
dc.subject | glutamate carboxypeptidase II, human | en |
dc.subject | membrane antigen | en |
dc.subject | monoclonal antibody | en |
dc.subject | radiopharmaceutical agent | en |
dc.subject | human | en |
dc.subject | isotope labeling | en |
dc.subject | molecular imaging | en |
dc.subject | nonhuman | en |
dc.subject | priority journal | en |
dc.subject | prostate cancer | en |
dc.subject | radioisotope diagnosis | en |
dc.subject | radioisotope therapy | en |
dc.subject | Review | en |
dc.subject | diagnostic imaging | en |
dc.subject | immunology | en |
dc.subject | isotope labeling | en |
dc.subject | male | en |
dc.subject | metabolism | en |
dc.subject | molecular imaging | en |
dc.subject | procedures | en |
dc.subject | prostate tumor | en |
dc.subject | Antibodies, Monoclonal | en |
dc.subject | Antigens, Surface | en |
dc.subject | Glutamate Carboxypeptidase II | en |
dc.subject | Humans | en |
dc.subject | Isotope Labeling | en |
dc.subject | Male | en |
dc.subject | Molecular Imaging | en |
dc.subject | Prostatic Neoplasms | en |
dc.subject | Radiopharmaceuticals | en |
dc.subject | Taylor and Francis Ltd | en |
dc.title | Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA | en |
dc.type | other | en |